Tanovea® (rabacfosadine for injection) 

Hundreds of reasons to treat canine lymphoma again

Tanovea® (rabacfosadine for injection) is the first and only FDA fully approved treatment for canine lymphoma, offering renewed confidence for a different approach at first rescue

Tanovea is proven effective in canine lymphoma and offers:

  • A novel mechanism of action (MOA) designed to target lymphoma¹

  • 73% Overall Response Rate (ORR)*

  • 151 days median progression-free survival (PFS) in responding dogs*

  • Convenient 3-week treatment intervals

Tanovea has been clinically proven to be effective at first rescue.

In a subgroup of 30 dogs with relapsed B-cell lymphoma that had received one prior chemotherapy regimen, Tanovea demonstrated:

Tanovea has an 83% overall response rate and a 63% complete response rate.

Choose a different option for canine lymphoma treatment with Tanovea

Tanovea® (rabacfosadine for injection) Resources

Product Detailer

Offer renewed confidence to treat canine lymphoma again with Tanovea

Tanovea is now the first and only FDA fully approved treatment for canine lymphoma, offering renewed confidence for a different approach at first rescue.

INDICATION: Tanovea is indicated for the treatment of lymphoma in dogs.

IMPORTANT SAFETY INFORMATION: Tanovea is not for use in humans.  Keep out of reach of children.  Do not come into direct contact with Tanovea.  Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment.  Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility.  Pregnant women, those who may become pregnant, and nursing women should not handle, prepare or administer the product.  Tanovea is associated with life-threatening or fatal pulmonary fibrosis.  Monitoring for signs of pulmonary dysfunction is recommended.  Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding.  Tanovea is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended.  Tanovea can cause neutropenia with nadir around seven days post-treatment.  Dogs should be frequently monitored for evidence of neutropenia during treatment.  Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia.

Please see Tanovea product label for full Prescribing Information.